ClinVar Miner

Submissions for variant NM_000203.5(IDUA):c.793G>C (p.Gly265Arg)

gnomAD frequency: 0.00003  dbSNP: rs369090960
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova RCV000790540 SCV000929872 likely pathogenic Mucopolysaccharidosis type 1 2019-01-01 criteria provided, single submitter literature only PS3: Low in vivo enzymatic activity in homozygote; low in vitro enzymatic activity. PM2: Very low frequency in ExAC. PP3: Multiple lines of computational evidence evidence supporting a deleterious effect
Labcorp Genetics (formerly Invitae), Labcorp RCV000790540 SCV001590399 pathogenic Mucopolysaccharidosis type 1 2023-06-09 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Experimental studies have shown that this missense change affects IDUA function (PMID: 15300847). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 638074). This missense change has been observed in individual(s) with Scheie or Hurler-Scheie syndrome, the attenuated forms of mucopolysaccharidosis type I (PMID: 15300847, 21394825, 31194252). This variant is present in population databases (rs369090960, gnomAD 0.001%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 265 of the IDUA protein (p.Gly265Arg). It affects a nucleotide within the consensus splice site.
Revvity Omics, Revvity RCV001784404 SCV002016685 likely pathogenic not provided 2021-09-21 criteria provided, single submitter clinical testing
Natera, Inc. RCV000790540 SCV002075316 pathogenic Mucopolysaccharidosis type 1 2021-09-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.